BioVie Analyst Ratings
BioVie Analyst Ratings
While ratings are subjective and will change, the latest BioVie (BIVI) rating was a reiterated with a price target of $0.00 to $12.00. The current price BioVie (BIVI) is trading at is $5.06, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/14/2023 | 137.15% | Oppenheimer | → $12 | Reiterates | → Outperform |
| 09/28/2022 | 58.1% | EF Hutton | $14 → $8 | Maintains | Buy |
| 07/22/2022 | 38.34% | Cantor Fitzgerald | → $7 | Initiates Coverage On | → Overweight |
| 03/17/2022 | 176.68% | EF Hutton | $9 → $14 | Maintains | Buy |
| 03/15/2022 | 77.87% | Oppenheimer | → $9 | Initiates Coverage On | → Outperform |
| 11/30/2021 | 433.6% | B. Riley Securities | $50 → $27 | Maintains | Buy |
| 01/15/2021 | 828.85% | B. Riley Securities | → $47 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 02/14/2023 | 137.15% | 奧本海默 | →$12 | 重申 | →跑贏大盤 |
| 09/28/2022 | 58.1% | EF Hutton | $14→$8 | 維護 | 買 |
| 07/22/2022 | 38.34% | 康託·菲茨傑拉德 | →$7 | 開始承保 | →超重 |
| 03/17/2022 | 176.68% | EF Hutton | $9→$14 | 維護 | 買 |
| 03/15/2022 | 77.87% | 奧本海默 | →$9 | 開始承保 | →跑贏大盤 |
| 2021年11月30日 | 433.6% | B.萊利證券 | $50→$27 | 維護 | 買 |
| 2021/01/15 | 828.85% | B.萊利證券 | →$47 | 開始承保 | →購買 |
What is the target price for BioVie (BIVI)?
BioVie(BIVI)的目標價格是多少？
The latest price target for BioVie (NASDAQ: BIVI) was reported by Oppenheimer on February 14, 2023. The analyst firm set a price target for $12.00 expecting BIVI to rise to within 12 months (a possible 137.15% upside). 5 analyst firms have reported ratings in the last year.
奧本海默於2023年2月14日報道了BioVie(納斯達克：BIVI)的最新目標價。這家分析公司將目標價定為12美元，預計BIVI將在12個月內升至(可能上漲137.15%)。去年有5家分析公司公佈了評級。
What is the most recent analyst rating for BioVie (BIVI)?
BioVie(BIVI)的最新分析師評級是多少？
The latest analyst rating for BioVie (NASDAQ: BIVI) was provided by Oppenheimer, and BioVie reiterated their outperform rating.
奧本海默提供了對BioVie(納斯達克代碼：BIVI)的最新分析師評級，BioVie重申了其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for BioVie (BIVI)?
BioVie(BIVI)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioVie, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioVie was filed on February 14, 2023 so you should expect the next rating to be made available sometime around February 14, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與BioVie的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。BioVie的上一次評級是在2023年2月14日提交的，所以你應該預計下一次評級將在2024年2月14日左右提供。
Is the Analyst Rating BioVie (BIVI) correct?
分析師對BioVie(BIVI)的評級正確嗎？
While ratings are subjective and will change, the latest BioVie (BIVI) rating was a reiterated with a price target of $0.00 to $12.00. The current price BioVie (BIVI) is trading at is $5.06, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的BioVie(BIVI)評級被重申，目標價在0.00美元至12.00美元之間。BioVie(BIVI)目前的交易價格為5.06美元，在分析師的預測範圍內。
